Clinical Research Directory
Browse clinical research sites, groups, and studies.
An Open-Label, FIH Study Evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in Subjects With T1D
Sponsor: CRISPR Therapeutics AG
Summary
This is an open-label, multicenter, Phase 1/2 study evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in Subjects with T1D
Official title: An Open-Label, First-in-Human Study Evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in Subjects With Type 1 Diabetes Mellitus (T1D)
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
40
Start Date
2023-01-20
Completion Date
2025-08
Last Updated
2024-05-23
Healthy Volunteers
No
Conditions
Interventions
VCTX211
CRISPR-Cas9 genetically modified PEC211 cells loaded into a delivery device
Locations (2)
University of Alberta
Edmonton, Alberta, Canada
University of British Columbia
Vancouver, British Columbia, Canada